Abstract
Protein tyrosine phosphorylation plays a major role in many cellular functions implicated in cancer development and progression, but only a few of the known protein tyrosine phosphatases have yet been clearly classified as oncogenes or tumor suppressors. PTPL1 interacts with tumor-associated proteins, suggesting a link between PTPL1, the PTPN13 gene product, and tumorigenesis or cancer progression. However, the impact of PTPL1 on cancer is divided between its capacity to counteract the activity of oncogenic tyrosine kinases and its inhibitory interaction with the death receptor, Fas. In this manuscript, we review the PTPL1-interacting proteins implicated in cancer. In addition, we examine the phenotypic arguments concerning both the PTPL1/Fas interaction and the ability of PTPL1 to inhibit signaling from growth factor receptors or oncogenes with tyrosine kinase activity. Finally, we compare the alterations in expression and the genetic and epigenetic arguments supporting an oncogenic or an anti-oncogenic impact of PTPL1.
Keywords: Cancer, Fas, Her2, Human papillomavirus 16, IRS-1, PTPN13, PTPL1, Src, TCF-dependent gene, PDZ-2, MCF7
Anti-Cancer Agents in Medicinal Chemistry
Title: PTPN13/PTPL1: An Important Regulator of Tumor Aggressiveness
Volume: 11 Issue: 1
Author(s): Gilles Freiss and Dany Chalbos
Affiliation:
Keywords: Cancer, Fas, Her2, Human papillomavirus 16, IRS-1, PTPN13, PTPL1, Src, TCF-dependent gene, PDZ-2, MCF7
Abstract: Protein tyrosine phosphorylation plays a major role in many cellular functions implicated in cancer development and progression, but only a few of the known protein tyrosine phosphatases have yet been clearly classified as oncogenes or tumor suppressors. PTPL1 interacts with tumor-associated proteins, suggesting a link between PTPL1, the PTPN13 gene product, and tumorigenesis or cancer progression. However, the impact of PTPL1 on cancer is divided between its capacity to counteract the activity of oncogenic tyrosine kinases and its inhibitory interaction with the death receptor, Fas. In this manuscript, we review the PTPL1-interacting proteins implicated in cancer. In addition, we examine the phenotypic arguments concerning both the PTPL1/Fas interaction and the ability of PTPL1 to inhibit signaling from growth factor receptors or oncogenes with tyrosine kinase activity. Finally, we compare the alterations in expression and the genetic and epigenetic arguments supporting an oncogenic or an anti-oncogenic impact of PTPL1.
Export Options
About this article
Cite this article as:
Freiss Gilles and Chalbos Dany, PTPN13/PTPL1: An Important Regulator of Tumor Aggressiveness, Anti-Cancer Agents in Medicinal Chemistry 2011; 11 (1) . https://dx.doi.org/10.2174/187152011794941262
DOI https://dx.doi.org/10.2174/187152011794941262 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Indoleamine 2,3-dioxygenase as a Modifier of Pathogenic Inflammation in Cancer and other Inflammation-Associated Diseases
Current Medicinal Chemistry Applications of Cellular Systems Biology in Breast Cancer Patient Stratification and Diagnostics
Combinatorial Chemistry & High Throughput Screening Dermatological, Cardiovascular and Neurological Morphohistopathological Effects of Fluoropyrimidine-based Chemotherapy in Humans
Clinical Cancer Drugs Nanoliposomal Encapsulation Enhances In Vivo Anti-Tumor Activity of Niclosamide against Melanoma
Anti-Cancer Agents in Medicinal Chemistry Ferroptosis: A Novel Mechanism of Artemisinin and its Derivatives in Cancer Therapy
Current Medicinal Chemistry A Mini-Review on Thalidomide: Chemistry, Mechanisms of Action, Therapeutic Potential and Anti-Angiogenic Properties in Multiple Myeloma
Current Medicinal Chemistry Advances in the Chemistry and Pharmacology of Ecteinascidins, A Promising New Class of Anticancer Agents
Current Medicinal Chemistry - Anti-Cancer Agents Drug Metabolism and Pharmacokinetics of Dammarane Triterpenoids
Current Drug Metabolism Radiative Effects on Boundary-Layer Flow of a Nanofluid on a Continuously Moving or Fixed Permeable Surface
Recent Patents on Mechanical Engineering Quantificational Methylation Analysis of APC and AXIN2 in HBV-related Hepatocellular Carcinoma
Current Cancer Therapy Reviews Recent Advances in Pegylated Interferon Antiviral Therapy of Chronic Hepatitis C
Anti-Infective Agents in Medicinal Chemistry Meet Our Editorial Board Member
Current Protein & Peptide Science Editorial (Thematic Issue: Improving Cancer Clinical Research and Trials with Hispanic Populations: Training and Outreach Efforts Between Moffitt Cancer Center and the Ponce School of Medicine)
Reviews on Recent Clinical Trials East-West Fusion–Necrosis and Apoptosis Acting in Concert by Demethylcantharidin-Integrated Platinum Complexes
Anti-Cancer Agents in Medicinal Chemistry Calmodulin in Complex with Proteins and Small Molecule Ligands: Operating with the Element of Surprise; Implications for Structure-Based Drug Design
Current Computer-Aided Drug Design Editorial (Thematic Issue: Current Research and Clinical Application in Head and Neck Radiotherapy)
Current Cancer Therapy Reviews Role of microRNAs in Osteoblasts Differentiation and Bone Disorders
Current Medicinal Chemistry Secondary Metabolites from Cyanobacteria: Complex Structures and Powerful Bioactivities
Current Organic Chemistry β2-Microglobulin-mediated Signaling as a Target for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Recent Progress in Biological Activities and Synthetic Methodologies of Pyrroloquinoxalines
Mini-Reviews in Medicinal Chemistry